peficitinib + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacokinetics of ASP015K
Conditions
Pharmacokinetics of ASP015K, Healthy Volunteer
Trial Timeline
Nov 18, 2009 → Mar 10, 2010
NCT ID
NCT01225224About peficitinib + Placebo
peficitinib + Placebo is a phase 1 stage product being developed by Astellas Pharma for Pharmacokinetics of ASP015K. The current trial status is completed. This product is registered under clinical trial identifier NCT01225224. Target conditions include Pharmacokinetics of ASP015K, Healthy Volunteer.
What happened to similar drugs?
5 of 5 similar drugs in Pharmacokinetics of ASP015K were approved
Approved (5) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01565655 | Phase 2 | Completed |
| NCT01649999 | Phase 2 | Completed |
| NCT01096862 | Phase 2 | Completed |
| NCT01225224 | Phase 1 | Completed |
Competing Products
20 competing products in Pharmacokinetics of ASP015K